1193 related articles for article (PubMed ID: 29935900)
21. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
22. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
23. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Agostinetto E; Debien V; Marta GN; Lambertini M; Piccart-Gebhart M; de Azambuja E
Eur J Clin Invest; 2021 Jul; 51(7):e13535. PubMed ID: 33662161
[TBL] [Abstract][Full Text] [Related]
25. Treating cancer with selective CDK4/6 inhibitors.
O'Leary B; Finn RS; Turner NC
Nat Rev Clin Oncol; 2016 Jul; 13(7):417-30. PubMed ID: 27030077
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
Lynce F; Shajahan-Haq AN; Swain SM
Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
[TBL] [Abstract][Full Text] [Related]
27. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
28. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
29. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.
Asghar US; Kanani R; Roylance R; Mittnacht S
JCO Precis Oncol; 2022 Jan; 6():e2100002. PubMed ID: 35005994
[TBL] [Abstract][Full Text] [Related]
30. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Coussy F; Deluche E; Pistilli B; Ladoire S; Ferrero JM; Cottu P
Bull Cancer; 2021 Sep; 108(9):843-854. PubMed ID: 34154797
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
32. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
34. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
35. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
36. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.
Micha JP; Rettenmaier MA; Bohart RD; Goldstein BH
J Oncol Pharm Pract; 2024 Apr; 30(3):547-551. PubMed ID: 38404005
[TBL] [Abstract][Full Text] [Related]
39. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
El Rassy E; Bakouny Z; Assi T; Kattan J
Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
[TBL] [Abstract][Full Text] [Related]
40. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]